Early detection of pancreatic cancer in the era of precision medicine

Taha M Ahmed; Satomi Kawamoto; Felipe Lopez-Ramirez; Mohammad Yasrab; Ralph H Hruban; Elliot K Fishman; Linda C Chu

doi:10.1007/s00261-024-04358-w

Early detection of pancreatic cancer in the era of precision medicine

Abdom Radiol (NY). 2024 May 18. doi: 10.1007/s00261-024-04358-w. Online ahead of print.

Authors

Taha M Ahmed¹, Satomi Kawamoto¹, Felipe Lopez-Ramirez¹, Mohammad Yasrab¹, Ralph H Hruban², Elliot K Fishman¹, Linda C Chu³

Affiliations

¹ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, MD, USA.
² Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, MD, USA. lindachu@jhmi.edu.

PMID: 38761272
DOI: 10.1007/s00261-024-04358-w

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality and it is often diagnosed at advanced stages due to non-specific clinical presentation. Disease detection at localized disease stage followed by surgical resection remains the only potentially curative treatment. In this era of precision medicine, a multifaceted approach to early detection of PDAC includes targeted screening in high-risk populations, serum biomarkers and "liquid biopsies", and artificial intelligence augmented tumor detection from radiologic examinations. In this review, we will review these emerging techniques in the early detection of PDAC.

Keywords: Artificial intelligence; CT; Cancer screening; Liquid biopsy; MRI; Pancreatic ductal adenocarcinoma.

Publication types

Review